Prolonged use of benzodiazepines in the elderly patient

Prolonged use of benzodiazepines in the elderly patient

Main Article Content

Marcelo Domínguez-Cantero

Abstract

The American and European societies of geriatrics support the withdrawal of benzodiazepines in elderly patients treated for a prolonged period, since its use is associated with balance disorders, falls, sedation and confusion. In our study we describe the use of benzodiazepines in patients older than 65 years. The population attended in an urban health center was selected. Prolonged treatment was defined as those lasting longer than six months. The data was obtained from the health card information system provided by the autonomous community. We identified patients older than 65 years treated with benzodiazepines from the electronic billing data of the prescriptions of these drugs dispensed in pharmacy offices during the period January-September 2016. Of the 19399 patients treated in this center, 6766 were over 65 years of age. 92.8% of patients older than 65 years were treated with benzodiazepines. 1263 used long-term benzodiazepines, 92.18% of the total. The usual practice differs from the recommendations on a limited use of benzodiazepines for a long time in elderly patients. Lormetazepan, lorazepam and alprazolam are the most prescribed benzodiazepines. These benzodiazepines can be prioritized when initiating programs of benzodiazepine deprescription in the population and propose other nonpharmacological alternatives to treat insomnia in the elderly.

References

Agencia Española del Medicamento y Productos Sanitarios (2013). Utilización de medicamentos
ansiolíticos e hipnóticos en España durante el período 2000-2012. Disponible en:
www.aemps.es

American Geriatrics Society (2015). Beers Criteria Update Expert Panel. American Geriatrics
Society. Updated Beers Criteria for Potentially Inappropriate Medication. Use in Older
Adults. Journal of the American Geriatrics Society, 63, 2227–2246.

Azparren, A., y García, I. (2014). Estrategias para la deprescripción de benzodiazepinas. Boletín
de Información Farmacoterapéutica de Navarra, 22(2), 1-12.

Catálogo de Medicamentos Consejo General de Colegios Oficiales Farmacéuticos (2018). Base de
datos Bot PLUS 2.0 del Consejo General de Colegios Oficiales de Farmacéuticos.
Cumming, R.G., y Le Conteur, D.G. (2003). Benzodiazepines and Risk of Hip Fractures in Older
People. CNS Drugs, 17(11), 825–837.

Danza, A., Cristiani, F., y Tamosiunas, G. (2009). Riesgos asociados al uso de benzodiazepinas.
Archivos de Medicina Interna, 4,103-107.

Delgado, E., Muñoz, M., Montero, B., Sánchez, C., Gallagher, P.F., y Cruz-Jentoft, A.J. (2009).
Inappropriate prescription in older patients: the STOPP/START criteria. Revista
Española de Geriatría y Gerontología, 44(5), 273-279.

Ficha técnica diazepam (2018). Base de datos Bot PLUS 2.0 del Consejo General de Colegios
Oficiales de Farmacéuticos.

Guía de Práctica Clínica para el Manejo de Pacientes con Insomnio en Atención Primaria (2009).
Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Política
Social. Unidad de Evaluación de Tecnologías Sanitarias. Comunidad de Madrid.
Disponible en: http://www.guiasalud.es/GPC/GPC_465_Insomnio_Lain_Entr_compl.pdf

Holt, S., Schmiedl, S., y Thürmann, P.A. (2010). Potentially Inappropriate Medications in the
Elderly: The PRISCUS List. Deutsches Ärzteblatt International,107, 543–551.

Madhusoodanan, S., y Bogunovic, O.J. (2004). Safety of benzodiazepines in the geriatric
population. Expert Opinion Drug Safety, 3(5), 485-493.

Mangoni, A.A., y Jackson, S.H.D. (2003). Age-related changes in pharmacokinetics and
pharmacodynamics: basic principles and practical applications. British Journal of
Clinical Pharmacology, 57(1), 6–14.

Pollmann, A.S., Murphy, A.L., Bergman J.C., y Gardner D.M. (2015). Deprescribing
benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC
Pharmacology and Toxicology, 4(16), 19.

Pottie, K., Thompson, W., Davies, S., Grenier, J., Sadowski, C.A., Welch, V., Farrell, B. (2018).
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice
guideline. Canadian Family Physician, 64(5), 339-351.

Weich, S., Pearce, H.L., Croft, P., Singh, S., Crome, I., Bashford, J., y Frisher, M. (2014). Effect
of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort
study. British Medical Journal, 19(348), 1-12.